|
Sunitinib Malate Clinical Trials
2 actively recruiting trials across 2 locations
Also known as: SU 011248, SU 11248, SU-011248, SU-11248, SU011248 +3 more
Pipeline
Phase 1: 1Phase 2: 1
Top Sponsors
- National Cancer Institute (NCI)1
- Dwight Owen1
Indications
- Cancer2
- Thymic Carcinoma1
- Unresectable Pancreatic Neuroendocrine Tumor1
- Stage IV Pancreatic Neuroendocrine Tumor AJCC v81
- Stage III Pancreatic Neuroendocrine Tumor AJCC v81
Duarte, California1 trial
Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors
City of Hope Comprehensive Cancer Center
Phase 1
Tampa, Florida1 trial
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.